224 related articles for article (PubMed ID: 2149050)
1. A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients.
Cony-Makhoul P; Brossard G; Marit G; Pellegrin JL; Texier-Maugein J; Reiffers J
Br J Haematol; 1990 Dec; 76 Suppl 2():35-40. PubMed ID: 2149050
[TBL] [Abstract][Full Text] [Related]
2. Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients.
Nucci M; Biasoli I; Braggio S; Portugal R; Schaffel R; Maiolino A; Loureiro MM; Spector N; Pulcheri W
Oncol Rep; 1998; 5(5):1205-9. PubMed ID: 9683836
[TBL] [Abstract][Full Text] [Related]
3. A randomized prospective study of ceftazidime and ciprofloxacin with or without teicoplanin as an empiric antibiotic regimen for febrile neutropenic patients.
Lim SH; Smith MP; Goldstone AH; Machin SJ
Br J Haematol; 1990 Dec; 76 Suppl 2():41-4. PubMed ID: 2149051
[TBL] [Abstract][Full Text] [Related]
4. Using teicoplanin for empiric therapy of febrile neutropenic patients with haematological malignancies.
Menichetti F; Del Favero A; Bucaneve G; Aversa F; Fiorio M
Br J Haematol; 1990 Dec; 76 Suppl 2():45-8. PubMed ID: 2149052
[TBL] [Abstract][Full Text] [Related]
5. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Gimema Infection Program.
Menichetti F; Martino P; Bucaneve G; Gentile G; D'Antonio D; Liso V; Ricci P; Nosari AM; Buelli M; Carotenuto M
Antimicrob Agents Chemother; 1994 Sep; 38(9):2041-6. PubMed ID: 7811016
[TBL] [Abstract][Full Text] [Related]
6. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients.
Vázquez L; Encinas MP; Morín LS; Vilches P; Gutiérrez N; García-Sanz R; Caballero D; Hurlé AD
Haematologica; 1999 Mar; 84(3):231-6. PubMed ID: 10189388
[TBL] [Abstract][Full Text] [Related]
7. Cefepime monotherapy as an empirical initial treatment of patients with febrile neutropenia.
Montalar J; Segura A; Bosch C; Galan A; Juan O; Molins C; Giner V; Aparicio J
Med Oncol; 2002; 19(3):161-6. PubMed ID: 12482126
[TBL] [Abstract][Full Text] [Related]
8. Prevention of gram-positive and Candida albicans infections using teicoplanin and fluconazole: a randomized study in neutropenic children.
Schaison G; Baruchel A; Arlet G
Br J Haematol; 1990 Dec; 76 Suppl 2():24-6. PubMed ID: 2149047
[TBL] [Abstract][Full Text] [Related]
9. [Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes].
Figuera A; Tomás JF; Hernández L; Jiménez ML; Peñarrubia MJ; del Rey MC; Arranz R; Cámara R; López-Lorenzo JL; Fernández-Rañada JM
Rev Clin Esp; 1996 Aug; 196(8):515-22. PubMed ID: 8984537
[TBL] [Abstract][Full Text] [Related]
10. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporin A-associated nephrotoxicity.
Kureishi A; Jewesson PJ; Rubinger M; Cole CD; Reece DE; Phillips GL; Smith JA; Chow AW
Antimicrob Agents Chemother; 1991 Nov; 35(11):2246-52. PubMed ID: 1839490
[TBL] [Abstract][Full Text] [Related]
11. An audit of efficacy and toxicity of teicoplanin versus vancomycin in febrile neutropenia: is the different toxicity profile clinically relevant?
Hahn-Ast C; Glasmacher A; Arns A; Mühling A; Orlopp K; Marklein G; Von Lilienfeld-Toal M
Infection; 2008 Feb; 36(1):54-8. PubMed ID: 18193385
[TBL] [Abstract][Full Text] [Related]
12. Role of glycopeptide antibiotics in the treatment of febrile neutropenic patients.
Smith SR; Cheesbrough J; Harding I; Davies JM
Br J Haematol; 1990 Dec; 76 Suppl 2():54-6. PubMed ID: 2149054
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient.
Ramphal R; Gucalp R; Rotstein C; Cimino M; Oblon D
Am J Med; 1996 Jun; 100(6A):83S-89S. PubMed ID: 8678102
[TBL] [Abstract][Full Text] [Related]
14. [The use of teicoplanin in neutropenic patients: values and limits].
Espinouse D; Chomarat M
Pathol Biol (Paris); 1990 Jun; 38(5 ( Pt 2)):552-6. PubMed ID: 2143573
[TBL] [Abstract][Full Text] [Related]
15. Teicoplanin in the treatment of gram-positive bacteraemia in neutropenic patients.
Micozzi A; Venditti M; Amadori S; Pulsoni A; Tirindelli C; Martino P
Br J Haematol; 1990 Dec; 76 Suppl 2():19-23. PubMed ID: 2149046
[TBL] [Abstract][Full Text] [Related]
16. Teicoplanin versus vancomycin in the empirical treatment of febrile neutropenic patients.
Chow AW; Jewesson PJ; Kureishi A; Phillips GL
Eur J Haematol Suppl; 1993; 54():18-24. PubMed ID: 8365461
[TBL] [Abstract][Full Text] [Related]
17. Three-step empiric treatment for severely neutropenic patients with fever: ceftazidime--vancomycin--amphotericin B.
Koeppler H; Pflueger KH; Seitz R; Havemann K
Infection; 1989; 17(3):142-5. PubMed ID: 2661438
[TBL] [Abstract][Full Text] [Related]
18. The role of gram-positive therapy in the neutropenic patient.
Menichetti F; Del Favero A
J Antimicrob Chemother; 1991 Apr; 27 Suppl B():51-60. PubMed ID: 1829077
[TBL] [Abstract][Full Text] [Related]
19. [Prospective and comparative study of 2 antibiotic therapy protocols in 66 febrile neutropenic patients. Ceftazidime-vancomycin versus ticarcillin-vancomycin-amikacin].
Brion JP; Bru JP; Michallet M; Corron B; Fauconnier J
Presse Med; 1988 Oct; 17(37):1964-7. PubMed ID: 2973597
[TBL] [Abstract][Full Text] [Related]
20. Neutropenic infections: a review of the French Febrile Aplasia Study Group trials in 608 febrile neutropenic patients.
Marie JP; Vekhoff A; Pico JL; Guy H; Andremont A; Richet H
J Antimicrob Chemother; 1998 Jun; 41 Suppl D():57-64. PubMed ID: 9688452
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
